Navigation Links
NDMA Launches Clinical Intelligence Platform
Date:10/17/2007

National Digital Medical Archive, Inc. (NDMA) introduces platform that leverages data contained within enterprise healthcare systems into clinical intelligence needed to help improve patient outcomes and reduce healthcare

costs

PHILADELPHIA, Oct. 17 /PRNewswire/ -- National Digital Medical Archive, Inc. (NDMA) today announced the availability of the NDMA Clinical Intelligence Platform to all healthcare providers around the country. Through NDMA, healthcare providers now have the ability to leverage all data contained within disparate healthcare system databases to better understand and manage their clinical operations in order to maximize performance. NDMA will also be used to identify opportunities to improve patient satisfaction and the quality of healthcare.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060809/PHW002LOGO )

NDMA's Clinical Intelligence Platform is the industry's first Clinical Intelligence (CI) solution that enables healthcare providers and payers to provide up-to-the-minute business information to empowering decision-makers across the organization. This information is used to identify emerging trends and enable stakeholders to immediately take action when problems arise that will positively affect their company's bottom line.

"Our platform is the only known technology that can easily snap into any healthcare IT environment leaving a small footprint, while also providing a single and consistent view of all complex data contained in disparate healthcare systems," stated Derek Danois, CEO, NDMA. "By leveraging our enabling technology, healthcare stakeholders can expect more value delivered from their healthcare system enterprise," added Danois.

The NDMA Clinical Intelligence (CI) Platform was developed to enable healthcare organizations to track, understand, and manage their clinical business o
'/>"/>

SOURCE National Digital Medical Archive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. Dr Reddy’s Laboratories launches Hyalosy
4. Serum Institute Launches New Tetanus-Diphtheria Vaccine
5. Scottish Health Minister Launches Organ Donor Plan
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
8. Pfizer Launches Viagra For Lung Disease In UK
9. PM Launches Healthcare Foundation For India
10. African Union Launches A Programme On Acceleration of HIV Prevention
11. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2